Supernus Pharma (SUPN) Misses Q1 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Supernus Announces First Quarter 2019 Financial Results
May 7, 2019 5:10 PM EDTTotal revenue of $85.5 million and net product sales of $83.1 million. Net product sales compare to $89.1 million in 2018 and were adversely impacted by approximately $10 million in channel inventory reduction in the first quarter, coupled with seasonal insurance plan dynamicsPrescription growth of 11% in 2019, for both Trokendi XR and Oxtellar XR, as compared to 2018Operating earnings of $25.4 million compared to $31.4 million in 2018. Operating earnings in 2019 were adversely affected by approximately $9.5 million, due to channel inventory reduction.In addition to channel inventory reduction, increase in effective tax rate to 24.3% in 1Q 2019, compared to 15.5% in 1Q 2018, which adversely... More
